INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 422m ago
HOUSE PTR22m ago
SEC 13F21m ago
ROBINHOOD CHAIN21m ago
SEC FORM 4/Grant or awardVerified data

Cavanaugh Sarah reported CLDX

SVP OF CORP AFFAIRS & ADMIN. · Celldex Therapeutics, Inc. · Celldex Therapeutics, Inc. — Incentive Stock Option (right to buy)

Side
A
Value
—
Shares
95.0K
Price
—
Executed
Jun 25, 2026
Disclosed
Jun 29, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 25 executedJun 29, 2026 disclosed

CLDX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CLDX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    JR
    Jain RitaDirector
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    26.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MB
    Martin Samuel BatesSVP AND CFO
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    93.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CE
    Crowley ElizabethSR. VP & CPDO
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    100.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LSVP & Chief Commercial Officer
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    90.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    5
    JA
    Jimenez Freddy A.SVP & GENERAL COUNSEL
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    93.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    TD
    Torres DeniceDirector
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    26.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    9
    HM
    Heath-Chiozzi MargoSVP OF REGULATORY AFFAIRS
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    95.0K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    28
    JA
    Jimenez Freddy A.SVP & GENERAL COUNSEL
    CLDXCelldex Therapeutics, Inc.
    Open-market sale
    		SELL$121K
    4,166 sh
    		Dec 4, 2025Dec 8, 2025
    traded Dec 4, 2025
    		+4dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LSVP & Chief Commercial Officer
    CLDXCelldex Therapeutics, Inc.
    Grant or award
    		A—
    100.0K sh
    		Nov 10, 2025Nov 12, 2025
    traded Nov 10, 2025
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001709113-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 25, 2026
    Published
    Jun 29, 2026
    Ingested by INSIDER
    Nov 5, 03:50 UTC
    Last re-read
    Nov 5, 03:50 UTC

    Extracted facts

    Filer
    Cavanaugh Sarah
    Role
    SVP OF CORP AFFAIRS & ADMIN.
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Celldex Therapeutics, Inc. — Incentive Stock Option (right to buy)
    Ticker
    CLDX
    Shares
    95.0K
    Price per share
    $0
    Execution date (reported)
    Jun 25, 2026
    Owned after transaction
    95.0K shares
    Days from execution to publication
    4

    What this establishes

    Cavanaugh Sarah filed this Form 4 reporting a grant or award of CLDX on Jun 25, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP OF CORP AFFAIRS & ADMIN.
    Cavanaugh Sarahcik:0001709113
    Issuer
    Celldex Therapeutics, Inc.cik:0000744218

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.